C4 Therapeutics, Inc.
HealthcareNASDAQ:CCCC · NASDAQ Global Select
+$0.03 today
Vol 2.85M · Avg 2.75M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$34.9M of revenue converted into -$103.8M of net income for the selected period. Gross margin is 92.7% and net margin is -320.9%, showing how much revenue survives after costs and taxes. EPS is $-1.19, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.9M +1.0% | $35.6M +71.4% | $20.8M -33.3% | $31.1M -32.1% | $45.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $8.0M | $0 -100.0% | $7.7M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $28.0M -21.4% | $35.6M +173.3% | $13.0M -58.1% | $31.1M -32.1% | $45.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 77.8% -22.2pp | 100.0% +37.3pp | 62.7% -37.3pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $104.2M -5.8% | $110.6M -6.0% | $117.7M -0.1% | $117.8M +24.5% | $94.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $36.2M -14.1% | $42.1M +0.1% | $42.1M -1.7% | $42.8M +28.7% | $33.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $132.5M -14.7% | $155.2M +2.1% | $152.1M -5.3% | $160.6M +25.6% | $127.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.0M +7.8% | $1.8M -76.5% | $7.7M +361.6% | $1.7M +12.3% | $1.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$102.9M +0.4% | -$103.4M +15.3% | -$122.1M +1.8% | -$124.3M -54.9% | -$80.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -286.3% +4.2pp | -290.5% +297.8pp | -588.3% -188.6pp | -399.7% -224.4pp | -175.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$104.5M +12.6% | -$119.6M +14.0% | -$139.0M -7.3% | -$129.5M -57.7% | -$82.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -290.7% +45.5pp | -336.1% +333.7pp | -669.8% -253.3pp | -416.6% -237.2pp | -179.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $14.4M +47.1% | $9.8M +174.5% | $3.6M +823.8% | $387.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $1.4M -38.0% | $2.2M +3.3% | $2.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$384.0K -102.7% | $14.4M +84.6% | $7.8M +475.3% | $1.4M +177.3% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$104.9M +0.3% | -$105.2M +19.8% | -$131.2M -2.4% | -$128.2M -52.8% | -$83.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -291.7% +3.9pp | -295.6% +336.6pp | -632.2% -220.0pp | -412.2% -229.0pp | -183.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $121.0K -7.6% | $131.0K -89.8% | $1.3M | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$105.0M +0.3% | -$105.3M +20.5% | -$132.5M -3.4% | -$128.2M -52.8% | -$83.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -292.1% +3.9pp | -296.0% +342.4pp | -638.3% -226.1pp | -412.2% -229.0pp | -183.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +16.4% | -$2 +43.1% | -$3 -1.9% | -$3 -44.0% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +16.4% | -$2 +43.1% | -$3 -1.9% | -$3 -44.0% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $82.9M +19.5% | $69.4M +39.8% | $49.6M +1.6% | $48.9M +6.1% | $46.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $82.9M +19.5% | $69.4M +39.8% | $49.6M +1.6% | $48.9M +6.1% | $46.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Cassava Sciences, Inc.
SAVA
$63.77M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CCCC generate?
C4 Therapeutics, Inc. (CCCC) reported $35.95M of revenue in fiscal 2025.
Is CCCC profitable?
C4 Therapeutics, Inc. (CCCC) reported -$104,994,000.00 of net income, with a net margin of -292.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.